KR920700682A - 글리코실화된 t-PA의 안정화방법 - Google Patents

글리코실화된 t-PA의 안정화방법

Info

Publication number
KR920700682A
KR920700682A KR1019910700926A KR910700926A KR920700682A KR 920700682 A KR920700682 A KR 920700682A KR 1019910700926 A KR1019910700926 A KR 1019910700926A KR 910700926 A KR910700926 A KR 910700926A KR 920700682 A KR920700682 A KR 920700682A
Authority
KR
South Korea
Prior art keywords
acid
pharmaceutical preparation
mmol
preparation according
sodium citrate
Prior art date
Application number
KR1019910700926A
Other languages
English (en)
Inventor
울리히 코너트
라이너 루돌프
Original Assignee
포우크베트·베버
뵈링거 만하임 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포우크베트·베버, 뵈링거 만하임 게엠베하 filed Critical 포우크베트·베버
Publication of KR920700682A publication Critical patent/KR920700682A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

글리코실화된 t-PA 의 안정화방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (21)

  1. a) 아스코르빈산, b)DETA, c) 일반식 R1R2N-R-X의 아미노 화합물, 식중 X는 SO3H, H,NH2또는 OH,R은 C1-9-알킬렌 C3-6, 시클로알킬렌 또는 벤질리덴, R1및 R2는 서로 무관하게 H또는 C1-3알킬, d)구아니디노부티르산, e) 디메틸바이구아나이드, f) 7-아미노헵탄산, 8-아미노옥탄산,p-아미노메틸벤조산, δ-아미노발레린산, γ-아미노부티르산, g) 글루코스아민, 플럭토스, h)피리미딘 뉴클레오시드 및 피리미딘 뉴졸에오타이드, i)하이드록실, 케토 및/ 또는 또다른 카복실 그룹중 하나이상으로 치환된 카복실산, 으로 구성된 그룹으로부터 선택된 최소한 하나의 화합물과 시트레이트를 함유하는 것을 특징으로 하는 활성이 최소한 1.4MU/ml이고 pH가 4.5-9인 t-PA활성을 지닌 글리코실화된 단백질의 의약 조성물.
  2. 제1항에 있어서, 아미노 화합물이 타우린, 4-아미노부탄올-1, 5-아미노펜탄올-1,6-아미노헥산올-1,1,9-디아미노노난, 1,8-디아미노옥탄, 1,7-디아미노헵탄, 1,6-디아미노헥산, 1,5-디아미노펜탄, 1,4-디아미노부탄 또는 1,3-디아미노프로판인것을 특징으로 하는 의약 제조물.
  3. 제1항에 있어서, 하나이상의 하이드록실, 케토 및/또는 또다른 카복실 그룹으로 치환된 카복실산이 사과산, 락트산, 퓨마르산 또는 2-옥소 글루타르산인 것을 특징으로 하는 의약 제조물.
  4. 제1항에 있어서, 부가적으로 하나 이상의 아미노산을 더 함유하는 것을 특징으로 하는 의약 제조물.
  5. 전기종 항중 어느 한 항에 있어서, 시트레이트의 농도가 5-100mmole/l, 바람직하게는 mmole/l, 인것을 특징으로 하는 의약 제조물.
  6. 전기종항중 어느 한 항에 있어서, 부가적으로 염화물이온을 더 포함하는 것을 특징으로 하는 의약 제조물.
  7. 제1항에 있어서, 1l당 50mmole의 나트륨 시트레이트, pH6, 0.1-1mole,바람직하게는 0.5-0.3mole의 아스코르빈산을 함유하는 것을 특징으로 하는 의약 제조물.
  8. 제1항에 있어서, 1l당 50mmole의 나트륨 시트레이트, pH6, 0-200mole,바람직하게는 10-100mole의 EDTA를 함유하는 것을 특징으로 하는 의약 제조물.
  9. 제1항에 있어서, 1l당 50mmole의 나트륨 시트레이트, pH6, 0.1-0.5mole,바람직하게는 0.1-0.3mole의 타우린을 함유하는 것을 특징으로 하는 의약 제조물.
  10. 제1항에 있어서, 1l당 50mmole의 나트륨 시트레이트/HC1, pH6, 10-100mole의 4-아미노부탄올, 1,5-아미노펜탄올-1,6-아미노헥산올-1,1,3-디아미노프로판, 1,4-디아미노부탄, 1,5-디아미노펜탄, 1,6-디아미노헥산, 1,7-디아미노헵탄, 1,8-디아미노옥탄 또는 1,9-디아미노노난을 함유하는 것을 특징으로 하는 의약 제조물.
  11. 제1항에 있어서, 1l당 50mmole의 나트륨 시트레이트/HC1, pH6, 10-200mole,바람직하게는 50-mmole의 구아니디노부티르산을 함유하는 것을 특징으로 하는 의약 제조물.
  12. 제1항에 있어서, 1l당 50mmole의 나트륨 시트레이트/HC1, pH6, 50-400mole,바람직하게는 100-300mmole의 디메틸바이구아나이드를 함유하는 것을 특징으로 하는 의약 제조물.
  13. 제1항에 있어서, 1l당 50mmole의 나트륨 시트레이트/HC1, pH6, 0.5-20mmole,바람직하게는 1-10mmole의 7-아미노헵탄산, 8-아미노옥탄산, δ-아미노발레린산, γ-아미노부티르산 또는 P-아미노메틸 벤조산을 함유하는 것을 특징으로 하는 의약 제조물.
  14. 제1항에 있어서, 1l당 50mmole의 나트륨 시트레이트/HC1, pH6, 1-500mmole,바람직하게는 10-300mmole의 글루코스아민 또는 플릭토스를 함유하는 것을 특징으로 하는 의약 제조물.
  15. 제1항에 있어서, 1l당 50mmole의 나트륨 시트레이트/HC1, pH6, 1-300mmole,바람직하게는 10-00mmole의 티미딘, 시토신 또는 유리딘을 함유하는 것을 특징으로 하는 의약 제조물.
  16. 제1항에 있어서, 1l당 50mmole의 나트륨 시트레이트, pH6, 1-1000mmole,바람직하게는 10-500mmole의 사과산, 락트산, 퓨마르산 또는 2-옥소글루타르산을 함유하는 것을 특징으로 하는 의약 제조물.
  17. 제1항에 있어서, 1l당 50mmole의 나트륨 시트레이트, pH6 및 제1항의 a)-i)그룹에서부터 선택된 물질들을 합한 것을 함유하는 것을 특징으로 하는 의약 제조물.
  18. 전기한 항중 어느 한 항의 조성물과 일반적으로 사용되는 의약용 부가제, 부형제 및/또는 담체 물질로 이루어진것을 특징으로 하는. 활성물질로서 t-PA 활성을 지닌 글리코실화된 단백질을 기본으로하는 의약 제조물.
  19. t-PA활성을 지닌 글리코실화된 단백질을 제1항의 a)-i)의 최소한 한 물질과 함께 투약하기에 적당한의약 형태로 전환시키는 것을 특징으로하는 제1-8중 어느 한 항의 의약 조성물을 제조하는 방법.
  20. 제19항에 있어서, 의약의 투약형태가 주사액이나 동격건조물인 것을 특징으로 하는 방법.
  21. 제1항부터 제18항중 어느 한 항의 의약 제조물을 만드는데 사용하는 t-PA 활성을 지닌 글리코실화된 단백질의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910700926A 1989-12-20 1990-12-19 글리코실화된 t-PA의 안정화방법 KR920700682A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEP39421422 1989-12-20
DE3942142A DE3942142A1 (de) 1989-12-20 1989-12-20 Stabilisierung von glykosyliertem t-pa
PCT/EP1990/002252 WO1991008767A1 (de) 1989-12-20 1990-12-19 STABILISIERUNG VON GLYKOSYLIERTEM t-PA

Publications (1)

Publication Number Publication Date
KR920700682A true KR920700682A (ko) 1992-08-10

Family

ID=6395925

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910700926A KR920700682A (ko) 1989-12-20 1990-12-19 글리코실화된 t-PA의 안정화방법

Country Status (9)

Country Link
US (1) US5409699A (ko)
EP (1) EP0458930B1 (ko)
JP (1) JPH0660107B2 (ko)
KR (1) KR920700682A (ko)
AU (1) AU625234B2 (ko)
CA (1) CA2046876A1 (ko)
DE (2) DE3942142A1 (ko)
HU (2) HUT60132A (ko)
WO (1) WO1991008767A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
DE3942145A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DK0643772T3 (da) * 1992-06-03 1998-02-02 Genentech Inc Glycosyleringsvarianter af vævsplasminogenaktivator med forbedrede terapeutiske egenskaber
US5679344A (en) * 1995-07-20 1997-10-21 Susan K. Williams Glucosamine composition and method
US6527979B2 (en) * 1999-08-27 2003-03-04 Corazon Technologies, Inc. Catheter systems and methods for their use in the treatment of calcified vascular occlusions
CA2403533C (en) * 2000-03-20 2014-12-30 Corazon Technologies, Inc. Methods and systems for enhancing fluid flow through an obstructed vascular site

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0156169B1 (en) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method
GR861037B (en) * 1985-04-22 1986-07-16 Genentech Inc Novel human tissue plasminogen activator mutants
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
GR861365B (en) * 1985-05-28 1986-09-29 Wellcome Found Novel formulation
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US4960702A (en) * 1985-09-06 1990-10-02 Codon Methods for recovery of tissue plasminogen activator
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
US5132214A (en) * 1986-04-09 1992-07-21 Monsanto Company Large scale production of plasminogen activator from normal human colon cells
US4927630A (en) * 1986-02-26 1990-05-22 Monsanto Company Tissue plasminogen activator from normal human colon cells
JPH0678241B2 (ja) * 1986-04-02 1994-10-05 エーザイ株式会社 ｔＰＡ医薬組成物
US5149533A (en) * 1987-06-04 1992-09-22 Zymogenetics, Inc. Modified t-PA with kringle-/replaced by another kringle
DE3718889A1 (de) * 1987-06-05 1988-12-22 Behringwerke Ag Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
US4935237A (en) * 1988-03-21 1990-06-19 Genentech, Inc. Processes for the preparation of t-PA mutants
US5100666A (en) * 1987-10-09 1992-03-31 Monsanto Company Modified tissue plasminogen activator K2K2SP
AU4187389A (en) * 1988-08-02 1990-03-05 Invitron Corporation Method for preparing tpa compositions
US5130143A (en) * 1988-11-04 1992-07-14 The Research Foundation Of State University Of New York Use of a low affinity-heparin fraction in conjunction with t-pa for thrombolytic therapy
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins

Also Published As

Publication number Publication date
JPH04506974A (ja) 1992-12-03
EP0458930A1 (de) 1991-12-04
AU625234B2 (en) 1992-07-02
JPH0660107B2 (ja) 1994-08-10
WO1991008767A1 (de) 1991-06-27
AU6914891A (en) 1991-07-18
HU208629B (en) 1993-12-28
HUT60132A (en) 1992-08-28
HU912739D0 (en) 1992-01-28
DE3942142A1 (de) 1991-06-27
CA2046876A1 (en) 1992-06-20
DE59003161D1 (de) 1993-11-25
EP0458930B1 (de) 1993-10-20
US5409699A (en) 1995-04-25

Similar Documents

Publication Publication Date Title
KR920700682A (ko) 글리코실화된 t-PA의 안정화방법
Prakash et al. Effect of α-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on L1210 leukemia in mice
Araki et al. A Pathway of Chitosan Formation in Mucor rouxii.
DE3579751D1 (de) Gluco-oligosaccharid-gemisch und verfahren zu seiner herstellung.
KR880014133A (ko) 금속성 은의 비전해 침작용 환원제 및 그 방법
BE904476A (fr) Solutions a base de phenytoine, leur procede de preparation et leur application pharmaceutique.
Friedman The effect of 5-azacytidine on E. coli DNA methylase
KR920700681A (ko) K₂P pro의 안정화
KR860003830A (ko) 가용화한 백금화합물 및 그 제조방법
KR920700684A (ko) t-PA pro의 안정화
ES388808A1 (es) Procedimiento para preparar composiciones enzimaticas de lavado.
Alhonen-Hongisto et al. Inhibition of polyamine accumulation and cell proliferation by derivatives of diaminopropane in Ehrlich ascites cells grown in culture
Kallio et al. Regulation of ornithine decarboxylase by diamines in regenerating rat liver
Käpyaho et al. Stimulation of melanotic expression in murine melanoma cells exposed to polyamine antimetabolites
Wallace et al. Acetylation of spermidine and methylglyoxal bis (guanylhydrazone) in baby-hamster kidney cells (BHK-21/C13)
KR920700685A (ko) K1K2P pro의 안정화
Kallio et al. Role of diamine oxidase during the treatment of tumour-bearing mice with combinations of polyamine anti-metabolites
Friedman et al. The inhibition of thymidine kinase in glial tumor cells by an amino sugar, D-glucosamine
Heston et al. Calmodulin antagonist inhibition of polyamine transport in prostatic cancer cells in vitro
IT1169774B (it) Composizioni terapeutiche iniettabili contenenti sali stabili della s-adenosil-l-metionina
Raisfeld Role of terminal substituents in the pulmonary toxicity of bleomycins
ES8405841A1 (es) Un metodo de producir una composicion pulverulenta, que contiene una serrapeptasa estabilizada.
ES2053623T3 (es) Procedimiento para la preparacion de enzimas fijadas a un soporte.
Aizawa et al. Antitumor effect of a baker's yeast mannan—mitomycin C conjugate against mouse hepatoma, MH134, in vivo and in vitro
KUNIMOTO et al. Cytotoxicity of spergualin and amine oxidase activity in medium

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application